** Shares of rare disease therapy developer Inozyme Pharma INZY.O rise 179% to $3.96 premarket
** BioMarin Pharma BMRN.O says that it has entered into an agreement to buy Inozyme Pharma for $4 per share in an all-cash transaction for a total consideration of around $270 million
** The deal is expected to close in Q3 2025
** The deal will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being assessed to treat a rare genetic disorder affecting blood vessels, soft tissues and bones, BMRN says
** As of last close, INZY down 48.7% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.